What’s Going On With Tilray Brands Stock Today?
Tilray Brands, Inc. (NASDAQ:TLRY) traded relatively flat in premarket on Thursday, after its medical division unveiled results from a newly published pharmacokinetic study comparing two cannabinoid delivery methods.
The study contributes to the growing body of research on the behavior of cannabinoid formulations in the human body, aiming to inform more therapeutic decisions for patients and healthcare providers.
The study compared how the body absorbs two THC: CBD formulations—an oral Tilray extract and a nabiximols oromucosal spray.
Also Read: Tilray Makes History, First To Import And Sell Branded Medical Cannabis In Italy
Researchers aimed to evaluate differences in absorption efficiency and pharmacokinetic responses.
The crossover pilot study, conducted in 12 fasting adult volunteers, measured blood levels of cannabinoids and their metabolites over a 24-hour period.
The study was conducted to assess comparative absorption levels, timelines, …